ATE357219T1 - Darreichungsformen für dns - Google Patents

Darreichungsformen für dns

Info

Publication number
ATE357219T1
ATE357219T1 AT03700947T AT03700947T ATE357219T1 AT E357219 T1 ATE357219 T1 AT E357219T1 AT 03700947 T AT03700947 T AT 03700947T AT 03700947 T AT03700947 T AT 03700947T AT E357219 T1 ATE357219 T1 AT E357219T1
Authority
AT
Austria
Prior art keywords
dna
present
dosage forms
skin
pharmaceutical agent
Prior art date
Application number
AT03700947T
Other languages
German (de)
English (en)
Inventor
Ian Richard Catchpole
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0201736.6A external-priority patent/GB0201736D0/en
Priority claimed from GB0201735A external-priority patent/GB0201735D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE357219T1 publication Critical patent/ATE357219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03700947T 2002-01-25 2003-01-23 Darreichungsformen für dns ATE357219T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
GB0201735A GB0201735D0 (en) 2002-01-25 2002-01-25 DNA dosage forms

Publications (1)

Publication Number Publication Date
ATE357219T1 true ATE357219T1 (de) 2007-04-15

Family

ID=27614803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03700947T ATE357219T1 (de) 2002-01-25 2003-01-23 Darreichungsformen für dns

Country Status (8)

Country Link
US (2) US20050085434A1 (https=)
EP (1) EP1467711B1 (https=)
JP (1) JP2005519905A (https=)
AT (1) ATE357219T1 (https=)
CA (1) CA2473717A1 (https=)
DE (1) DE60312645T2 (https=)
ES (1) ES2285087T3 (https=)
WO (1) WO2003061629A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235558T1 (de) * 1989-06-26 2003-04-15 Powderject Vaccines Inc Transformation von tierischen somatischen zellen mittels partikeln
DK28792D0 (da) * 1992-03-04 1992-03-04 Novo Nordisk As Nyt enzym
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
ES2208687T3 (es) * 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EP0906110B1 (en) * 1996-04-26 2004-12-22 Merck & Co., Inc. Dna vaccine formulations

Also Published As

Publication number Publication date
US20050085434A1 (en) 2005-04-21
WO2003061629A2 (en) 2003-07-31
WO2003061629A3 (en) 2003-10-02
JP2005519905A (ja) 2005-07-07
DE60312645T2 (de) 2007-11-29
EP1467711B1 (en) 2007-03-21
ES2285087T3 (es) 2007-11-16
US20080095854A1 (en) 2008-04-24
DE60312645D1 (de) 2007-05-03
CA2473717A1 (en) 2003-07-31
EP1467711A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
MXPA04009163A (es) Nuevos compuestos.
TW200510375A (en) New compounds
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EE200200343A (et) Asaindooli sisaldav farmatseutiline kompositsioonraviotstarbeliseks kasutamiseks, asaindoolid ningnende kasutamine ravimite valmistamiseks, mis on ette nähtud proteiinikinaasi katalüütilise toime pärssimiseks
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
HRP20050822B1 (hr) Formulacija za inhalator s odmjerenom dozom koji koristi hidro-fluoro-alkane kao propelente
NO20065878L (no) Terapeutiske forbindelser
BR0213358A (pt) Uso de flibanserina
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
FR2889811B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
SE0302546D0 (sv) New compounds
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
EP1602362A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ACTIVE INGREDIENTS HAVING A HIGH CONCENTRATION ON A BALL-MOLDED CORE
BR0015538B1 (pt) emprego de polissiloxanos com grupos amino quaternÁrios como coadjuvantes de formulaÇço, agentes contendo-os, bem como tubos de polipropileno de dose énica contendo os referidos agentes.
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
DE60312645D1 (de) Darreichungsformen für dns
ITRM20030596A1 (it) Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
AR022462A1 (es) Uso de un agente que disminuye el colesterol
DE50005714D1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
GB0028245D0 (en) New therapeutic use
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties